Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 4, 2013, Pages 834-840

  Jit, Mark ^a,b   Newall, Anthony T ^c   Beutels, Philippe ^c,d  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Burden of disease; Cost effectiveness analysis; Influenza; Influenza vaccination; Surveillance; Vaccine effectiveness

Indexed keywords

INFLUENZA VACCINE;

ABSENTEEISM; ACUTE RESPIRATORY TRACT DISEASE; ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ECONOMIC EVALUATION; FLU LIKE SYNDROME; HEALTH CARE COST; HUMAN; INFLUENZA VACCINATION; POLICY; SEASONAL INFLUENZA; VIRUS IMMUNITY; VIRUS LOAD; VIRUS VIRULENCE;

BURDEN OF DISEASE; COST-EFFECTIVENESS ANALYSIS; INFLUENZA; INFLUENZA VACCINATION; SURVEILLANCE; VACCINE EFFECTIVENESS;

COST-BENEFIT ANALYSIS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION;

EID: 84877145716     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23637     Document Type: Article

References (53)

1. Ng S, Wu P, Nishiura H, Ip DK, Lee ES, Cowling BJ. An analysis of national target groups for monovalent 2009 pandemic influenza vaccine and trivalent seasonal influenza vaccines in 2009-10 and 2010-11. BMC Infect Dis 2011; 11:230; PMID:21871096; http://dx.doi.org/10.1186/1471-2334-11-230.
2. Hombach J. Seasonal influenza vaccine policy and utilization: a global perspective. www.who.int/entity/influ-enza-vaccines-plan/resources/hombach.pdf. Accessed on 1 Oct 2012. www.who.int/entity/influenza-vac-cines-plan/resources/ hombach.pdf. 2012.
3. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59(RR-8):1-62; PMID:20689501.
4. Department of Health. JCVI statement on the annual influenza vaccination programme-extension of the programme to children, 25 July 2012. https://www.wp.dh.gov.uk/transparency/files/2012/07/JCVI-statement-on-the- annual-influenza-vaccination-programme-25-July-2012.pdf. Accessedon27November2011.https://www.wp.dh.gov.uk/transparency/files/2012/07/ JCVI-statement-on-the-annual-influenza-vaccination-programme-25-July-2012.pdf. 2012.
5. Mereckiene J, Cotter S, D'Ancona F, Giambi C, Nicoll A, Levy-Bruhl D, et al.; VENICE project gatekeepers group. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. Euro Surveill 2010; 15:15; PMID:21087586.
6. National Advisory Committee on Immunization (NACI). Statement on Seasonal Influenza Vaccine for 2012-2013. Can Commun Dis Rep 2012; 130:38.
7. Department of Health of the Government of the Hong Kong Special Administrative Region. Scientific Committee's recommendations on influenza vaccination for 2012/13 season. http://www.dh.gov.hk/eng-lish/press/2012/120726- 2.html.Accessedon9January2013.2013.
8. World Health Organization. Report of the second WHO Consultation of the Global Action Plan for Influenza Vaccines (GAP). 1-1-2011.
9. Vaccines against influenza WHO position paper-November 2012. Wkly Epidemiol Rec 2012; 87:461-76; PMID:23210147.
10. Nicholson KG. Clinical features of influenza. Semin Respir Infect 1992; 7:26-37; PMID:1609165.
11. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86; PMID:12517228; http://dx.doi.org/10.1001/ jama.289.2.179.
12. Klick B, Nishiura H, Cowling BJ. Optimal design of intervention studies to prevent influenza in healthy cohorts. PLoS One 2012; 7:e35166; PMID:22514718; http://dx.doi.org/10.1371/journal.pone.0035166.
13. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. Overview of Influenza Surveillance in the United States. October 5, 2012. http://www.cdc.gov/flu/pdf/weekly/overview.pdf. Accessedon27October2012.http://www.cdc.gov/flu/pdf/weekly/overview.pdf.2012.
14. World Health Organization. WHO global technical consultation: global standards and tools for infuenza surveillance. Geneva, Switzerland, 8-10 March 2011. http://whqlibdoc.who.int/hq/2011/WHO-HSE-GIP-2011.1-eng.pdf. Accessedon27November2012.http://whqlibdoc.who.int/hq/2011/WHO-HSE-GIP-2011. 1-eng.pdf.2012.
15. Barker WH, Mullooly J P. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med 1982; 142:85-9; PMID:7053739; http://dx.doi.org/10.1001/archinte.1982.00340140087016.
16. Navarro-Marí JM, Pérez-Ruiz M, Cantudo-Muñoz P, Petit-Gancedo C, Jiménez-Valera M, Rosa-Fraile M; Influenza Surveillance Network in Andalusia, Spain. Influenza-like illness criteria were poorly related to laboratory-confirmed influenza in a sentinel surveillance study. J Clin Epidemiol 2005; 58:275-9; PMID:15768487; http://dx.doi.org/10.1016/j.jcline-pi. 2004.08.014.
17. Newall AT, Jit M, Beutels P. Economic evaluations of childhood influenza vaccination: a critical review. Pharmacoeconomics 2012; 30:647-60; PMID:22788257; http://dx.doi.org/10.2165/11599130-000000000-00000.
18. Newall AT, Viboud C, Wood JG. Influenza-attributable mortality in Australians aged more than 50 years: a comparison of different modelling approaches. Epidemiol Infect 2010; 138:836-42; PMID:19941685; http://dx.doi.org/10.1017/S095026880999118X.
19. Newall AT, Wood JG, Macintyre CR. Influenza-related hospitalisation and death in Australians aged 50 years and older. Vaccine 2008; 26:2135-41; PMID:18325639; http://dx.doi.org/10.1016/j.vac-cine.2008.01.051.
20. Simonsen L, Clarke MJ, Williamson GD, Stroup D F, Arden NH, Schonberger LB. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997; 87:1944-50; PMID:9431281; http://dx.doi.org/10. 2105/AJPH.87.12.1944.
21. Serfling RE. Methods for current statistical analysis of excess pneumonia-influenza deaths. Public Health Rep 1963; 78:494-506; PMID:19316455; http://dx.doi.org/10.2307/4591848.
22. Drummond M F, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Third edition. Oxford: Oxford University Press. 2005.
23. Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect Dis 2008; 8:727-33; PMID:18992409; http://dx.doi.org/10.1016/S1473-3099(08)70258-5.
24. Keech M, Beardsworth P. The impact of influenza on working days lost: a review of the literature. Pharmacoeconomics 2008; 26:911-24; PMID:18850761; http://dx.doi.org/10.2165/00019053-200826110-00004.
25. Koopmanschap MA, Rutten F F. The impact of indirect costs on outcomes of health care programs. Health Econ 1994; 3:385-93; PMID:9435921; http://dx.doi.org/10.1002/hec.4730030606.
26. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14:171-89; PMID:10154656; http://dx.doi.org/10.1016/0167-6296(94)00044-5.
27. Weinstein MC, Siegel JE, Garber AM, Lipscomb J, Luce BR, Manning WG Jr., et al. Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. Health Econ 1997; 6:505-10; PMID:9353651; http://dx.doi.org/10.1002/(SICI)1099-1050(199709)6:5505::AID-HEC2943.0.CO;2-I.
28. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998; 13:1-7; PMID:10175982; http://dx.doi.org/10.2165/ 00019053-199813010-00001.
29. Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 1996; 174(Suppl 3):S335-41; PMID:8896542; http://dx.doi.org/10.1093/infdis/174. Supplement-3.S335.
30. Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and "no medical care" disease impact in Belgium. Med Decis Making 2009; 29:33-50; PMID:18948433; http://dx.doi.org/10.1177/0272989X08324955.
31. Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother 1999; 44 Suppl B:11-15.
32. Wynne-Jones G, Mallen CD, Welsh V, Dunn KM. Rates of sickness certification in European primary care: a systematic review. Eur J Gen Pract 2008; 14:99-108; PMID:19153887; http://dx.doi.org/10.1080/13814780802687521.
33. Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur Respir J 2001; 17:1282-93; PMID:11491177; http://dx.doi.org/10.1183/09031936.01. 00084301.
34. McCullers JA, Huber VC. Correlates of vaccine protection from influenza and its complications. Hum Vaccin Immunother 2012; 8:34-44; PMID:22252001.
35. Schanzer DL, Garner MJ, Hatchette T F, Langley JM, Aziz S, Tam T W. Estimating sensitivity of laboratory testing for influenza in Canada through modelling. PLoS One 2009; 4:e6681; PMID:19688094; http://dx.doi.org/10.1371/ journal.pone.0006681.
36. Kelly H, Newall AT. Mortality benefits of influenza vaccination in elderly people. Lancet Infect Dis 2008; 8:462-3, author reply 463-5; PMID:18652991; http://dx.doi.org/10.1016/S1473-3099(08)70163-4.
37. Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in clinical trials. Lancet Infect Dis 2011; 11:482-7; PMID:21616458; http://dx.doi.org/10.1016/S1473-3099(10)70318-2.
38. Esposito S, Marchisio P, Bosis S, Lambertini L, Claut L, Faelli N, et al. Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. Vaccine 2006; 24:629-35; PMID:16157429; http://dx.doi.org/10.1016/j. vaccine.2005.08.054.
39. Piedra PA, Gaglani MJ, Kozinetz CA, Herschler G, Riggs M, Griffith M, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005; 23:1540-8; PMID:15694506; http://dx.doi.org/10.1016/j.vaccine.2004.09.025.
40. Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM, et al. Economic appraisal of Ontario°s Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med 2010; 7:e1000256; PMID:20386727; http://dx.doi.org/10.1371/journal.pmed.1000256.
41. Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med 2002; 156:986-91; PMID:12361443.
42. Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 2011; 29:371-86; PMID:21504239; http://dx.doi.org/10.2165/11539960-000000000-00000.
43. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26:191-215; PMID:18282015; http://dx.doi.org/10.2165/00019053-200826030-00004.
44. Baguelin M, Jit M, Miller E, Edmunds WJ. Health and economic impact of the seasonal influenza vaccination programme in England. Vaccine 2012; 30:3459-62; PMID:22446636; http://dx.doi.org/10.1016/j.vac-cine.2012.03.019.
45. de Waure C, Veneziano MA, Cadeddu C, Capizzi S, Specchia ML, Capri S, et al. Economic value of influenza vaccination. Hum Vaccin Immunother 2012; 8:119-29; PMID:22251999.
46. Coleman MS, Washington ML, Orenstein WA, Gazmararian JA, Prill MM. Interdisciplinary epide-miologic and economic research needed to support a universal childhood influenza vaccination policy. Epidemiol Rev 2006; 28:41-6; PMID:16740584; http://dx.doi.org/10.1093/epirev/mxj008.
47. Nichol KL. Cost-effectiveness and socio-economic aspects of childhood influenza vaccination. Vaccine 2011; 29:7554-8; PMID:21820477; http://dx.doi.org/10.1016/j.vaccine.2011.08.015.
48. Savidan E, Chevat C, Marsh G. Economic evidence of influenza vaccination in children. Health Policy 2008; 86:142-52; PMID:18054109; http://dx.doi.org/10. 1016/j.healthpol.2007.09.009.
49. Gatwood J, Meltzer MI, Messonnier M, Ortega-Sanchez IR, Balkrishnan R, Prosser LA. Seasonal influenza vaccination of healthy working-age adults: a review of economic evaluations. Drugs 2012; 72:35-48; PMID:22191794; http://dx.doi.org/10.2165/11597310-000000000-00000.
50. Hogan TJ. Issues in the economic evaluation of influenza vaccination by injection of healthy working adults in the US: a review and decision analysis of ten published studies. Pharmacoeconomics 2012; 30:355-71; PMID:22462695; http://dx.doi.org/10.2165/11596890-000000000-00000.
51. Newall AT, Kelly H, Harsley S, Scuffham PA. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50-to 64-year age group. Pharmacoeconomics 2009; 27:439-50; PMID:19640008; http://dx.doi.org/10.2165/00019053-200927060-00001.
52. Burls A, Jordan R, Barton P, Olowokure B, Wake B, Albon E, et al. Vaccinating healthcare workers against influenza to protect the vulnerable-is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation. Vaccine 2006; 24:4212-21; PMID:16546308; http://dx.doi.org/10.1016/j.vaccine.2005.12.043.
53. Postma MJ, Baltussen R P, Palache AM, Wilschut JC. Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Rev Pharmacoecon Outcomes Res 2006; 6:215-27; PMID:20528557; http://dx.doi.org/10. 1586/14737167.6.2.215.